Stephanie Du Four

1.1k citations

34 papers · 834 indexed · h-index 15

Oncology top 10%
Molecular Biology
Genetics top 5%
Immunology top 10%
Pulmonary and Respiratory Medicine top 10%

Co-authors: Bart Neyns Johnny Duerinck Alex Michotte Sarah Maenhout Kris Thielemans Sofie Wilgenhof Hendrik Everaert Joeri L. Aerts
Topics: Glioma Diagnosis and Treatment (16 papers)Brain Metastases and Treatment (10 papers)Cancer Immunotherapy and Biomarkers (9 papers)
Cited by: Genetics Oncology Immunology
Journals: Journal of Clinical OncologySHILAP Revista de lepidopterologíaNeurosurgery
Partner nations: Belgium Australia Netherlands

In The Last Decade

Stephanie Du Four

31 papers receiving 822 citations

Peers

Countries citing papers authored by Stephanie Du Four

Since Specialization

Citations

This map shows the geographic impact of Stephanie Du Four's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephanie Du Four with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephanie Du Four more than expected).

Fields of papers citing papers by Stephanie Du Four

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephanie Du Four. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephanie Du Four. The network helps show where Stephanie Du Four may publish in the future.

Co-authorship network of co-authors of Stephanie Du Four

This figure shows the co-authorship network connecting the top 25 collaborators of Stephanie Du Four. A scholar is included among the top collaborators of Stephanie Du Four based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephanie Du Four. Stephanie Du Four is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Deep brain stimulation in Bassen-Kornzweig syndrome: Still effective after 22 years 2023 ·SHILAP Revista de lepidopterología ·(unknown),Sarah Vandamme,Dimitri Vanhauwaert,(unknown),(unknown),Peter I. Tack,Stephanie Du Four,(unknown)	0
2	Pituitary carcinoma - case series and review of the literature 2022 ·Frontiers in Endocrinology ·Stephanie Du Four,(unknown),Johnny Duerinck,(unknown),Corina Andreescu,Michaël Bruneau,Bart Neyns,(unknown),Brigitte Velkeniers	11
3	Quality indicators in neuro-oncology: Review of the literature and development of a new quality indicator set for glioma care through a two-round Delphi survey 2022 ·Journal of Neuro-Oncology ·Dimitri Vanhauwaert,(unknown),(unknown),Stephanie Du Four,Liesbet Van Eycken,Steven De Vleeschouwer,F. Weyns,Florence Lefranc,Ludo Vanopdenbosch,Alex Michotte,Tom Boterberg,(unknown),Martin Lammens,Paul W. Clement,Nicolas Whenham,(unknown),(unknown),Serge Goldman,Ingeborg Goethals,Harlinde De Schutter	6
4	Randomized Trial Comparing Burr Hole Craniostomy, Minicraniotomy, and Twist Drill Craniostomy for Treatment of Chronic Subdural Hematoma 2022 ·Neurosurgery ·Johnny Duerinck,(unknown),Sophie Schuind,Frank Van Calenbergh,J. van Loon,Stephanie Du Four,(unknown),(unknown),Christian Raftopoulos,Olivier De Witte,Wilfried Cools,Ronald Buyl,Vera Van Velthoven,Jean D’Haens,Michaël Bruneau	25
5	Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx) 2020 ·Journal for ImmunoTherapy of Cancer ·Gil Awada,(unknown),Jennifer Cremer,Julia Katharina Schwarze,(unknown),Laura Seynaeve,Stephanie Du Four,Anne‐Marie Vanbinst,Alex Michotte,Hendrik Everaert,Anne Rogiers,Peter Theuns,Johnny Duerinck,Bart Neyns	42
6	Early-Onset Creutzfeldt-Jakob Disease Mimicking Immune-Mediated Encephalitis 2018 ·Frontiers in Neurology ·(unknown),Stephanie Du Four,Laura Seynaeve,Anja Flamez,Thomas Tousseyn,Dietmar Rudolf Thal,Miguel D’haeseleer	6
7	Meningoencephaloradiculitis following infection with tick borne encephalitis virus: case report and review of the literature 2018 ·Acta Neurologica Belgica ·Stephanie Du Four,(unknown),(unknown),Jacques De Keyser,(unknown),Anja Flamez	5
8	Safety of axitinib plus avelumab in patients with recurrent glioblastoma. 2018 ·Journal of Clinical Oncology ·(unknown),Johnny Duerinck,Stephanie Du Four,Gil Awada,(unknown),Jennifer Cremer,Anne Rogiers,Bart Neyns	4
9	Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma 2017 ·Journal of Neuro-Oncology ·Johnny Duerinck,Stephanie Du Four,Frank Bouttens,Claire André,Vincent Verschaeve,(unknown),C. Chaskis,Nicky D’Haene,Marie Le Mercier,Anne Rogiers,Alex Michotte,Isabelle Salmon,Bart Neyns	52
10	Intratumoral Delivery of TriMix mRNA Results in T-cell Activation by Cross-Presenting Dendritic Cells 2016 ·Cancer Immunology Research ·Sandra Van Lint,Dries Renmans,Katrijn Broos,Lode Goethals,Sarah Maenhout,Daphné Benteyn,Cleo Goyvaerts,Stephanie Du Four,Kevin Van der Jeught,Lukasz Bialkowski,Véronique Flamand,Carlo Heirman,Kris Thielemans,Karine Breckpot	101
11	Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion 2016 ·Cancer Immunology Immunotherapy ·Stephanie Du Four,Sarah Maenhout,Daphné Benteyn,Brenda De Keersmaecker,Johnny Duerinck,Kris Thielemans,Bart Neyns,Joeri L. Aerts	37
12	Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma 2016 ·Journal of Neuro-Oncology ·Johnny Duerinck,Stephanie Du Four,Fenne Vandervorst,Nicky D’Haene,Marie Le Mercier,Alex Michotte,(unknown),Hendrik Everaert,Isabelle Salmon,Frank Bouttens,Vincent Verschaeve,Bart Neyns	41
13	Bone Marrow Metastases from a 1p/19q Co-deleted Oligodendroglioma - A Case Report. 2016 ·PubMed ·(unknown),Johnny Duerinck,Stephanie Du Four,Karel Fostier,Alex Michotte,Bart Neyns	3
14	Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model 2015 ·OncoImmunology ·Stephanie Du Four,Sarah Maenhout,(unknown),Dries Renmans,Simone P. Niclou,Kris Thielemans,Bart Neyns,Joeri L. Aerts	63
15	Symptomatic Histologically Proven Necrosis of Brain following Stereotactic Radiation and Ipilimumab in Six Lesions in Four Melanoma Patients 2014 ·Case Reports in Oncological Medicine ·Stephanie Du Four,Angela Hong,Matthew Chan,(unknown),Johnny Duerinck,Sofie Wilgenhof,Wei Wang,(unknown),Alex Michotte,Meena Okera,Brindha Shivalingam,Gerald B. Fogarty,Richard Kefford,Bart Neyns	33
16	Randomized phase II study of axitinib versus standard of care in patients with recurrent glioblastoma. 2014 ·Journal of Clinical Oncology ·Bart Neyns,Johnny Duerinck,Stephanie Du Four,Frank Bouttens,Vincent Verschaeve,Hendrik Everaert,(unknown)	3
17	Single-Center Experience With Ipilimumab in an Expanded Access Program for Patients With Pretreated Advanced Melanoma 2013 ·Journal of Immunotherapy ·Sofie Wilgenhof,Stephanie Du Four,Frederik Vandenbroucke,Hendrik Everaert,Isabelle Salmon,Danielle Líénard,V. del Mármol,Bart Neyns	64
18	Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab 2012 ·International Journal of Oncology ·(unknown),Erik Teugels,Jan Sadones,Sylvia De Brakeleer,Johnny Duerinck,Stephanie Du Four,Alex Michotte,Jacques De Grève,Bart Neyns	56
19	Patterns of Response in Patients with Pretreated Metastatic Melanoma who Received Ipilimumab 3 mg/kg in a European Expanded Access Program: Five Illustrative Case Reports 2012 ·Cancer Investigation ·Sofie Wilgenhof,Stephanie Du Four,Hendrik Everaert,Bart Neyns	8
20	Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor. 2012 ·PubMed ·Sofie Wilgenhof,(unknown),(unknown),Stephanie Du Four,(unknown),Shane Hanon,Frederik Vandenbroucke,Hendrik Everaert,Bart Neyns	66

About Stephanie Du Four

Stephanie Du Four is a scholar working on Genetics, Oncology and Pulmonary and Respiratory Medicine, having authored 34 papers that have together received 834 indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (16 papers), Brain Metastases and Treatment (10 papers) and Cancer Immunotherapy and Biomarkers (9 papers). The work is most often cited by research in Genetics (280 citations), Oncology (435 citations) and Immunology (264 citations). Stephanie Du Four has collaborated with scholars based in Belgium, Australia and Netherlands. Frequent co-authors include Bart Neyns, Johnny Duerinck, Alex Michotte, Sarah Maenhout, Kris Thielemans, Sofie Wilgenhof, Hendrik Everaert, Joeri L. Aerts, Simone P. Niclou and Isabelle Salmon. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Neurosurgery.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact